Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”) announced that its board resolved on 28 April 2026 to terminate the Post-IPO Restricted Share Unit (RSU) Scheme adopted on 27 May 2019. Although the original plan was designed to run for ten years from the 14 June 2019 listing date, it will cease once the company’s proposed 2026 Share Scheme is approved. All unvested awards previously granted will remain valid, but no additional awards will be issued under the terminated plan.

Management cited the updated Chapter 17 of Hong Kong’s Listing Rules—effective 1 January 2023—as the catalyst for revising its equity incentive framework, noting that the new structure better aligns with prevailing market practice and the Group’s long-term objectives.

The proposed 2026 Share Scheme will allow the grant of both RSUs and options, funded by newly issued shares, existing shares, and/or treasury shares. As the plan involves potential issuance of new shares, it must comply with Chapter 17 requirements. Implementation is contingent on two approvals: ordinary resolutions at the forthcoming annual general meeting (AGM) and listing consent from the Hong Kong Stock Exchange’s listing committee for any new shares allotted under future awards.

Hansoh Pharma will circulate detailed documentation, including the New Share Scheme rules and AGM notice, in due course.